Phase III amlenetug trial months away, Lundbeck says

CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA.

Amlenetug, a human monoclonal antibody that recognizes and binds to all major forms of extracellular α-syn and is thereby believed to prevent uptake and inhibit seeding of aggregation, is being developed by Lundbeck under a joint research and licensing agreement with fellow Danish firm Genmab (CPH: GMAB).

Lundbeck describes the TALISMAN study as a step forward in its commitment to understanding the course of MSA and developing innovative therapies that address significant unmet needs in the devastating and rapidly progressive disease.